ERBB2 and cancer: This cohort of patients were traditionally not considered eligible for HER2-targeted therapies, but T-DXd’s ability to kill cancer cells through its potent cytotoxic payload and bystander effect (where the drug affects neighbouring cancer cells regardless of HER2 status) has led to significant clinical responses.